GDF-15

Mechanism

A stress-responsive hormone that acts as the body's endogenous "sickness signal" — it powerfully suppresses appetite by acting on a specific receptor in the brainstem. GDF-15 is elevated during cancer (causing cachexia/wasting), pregnancy (contributing to morning sickness), and metformin use (partly explaining its weight loss effects). Pharmaceutical companies are now developing GDF-15-based obesity drugs.

Effects

## GDF-15 — System-by-System Effects ### Metabolic/Appetite System (Primary) - **GFRAL receptor activation**: GDF-15 (Growth Differentiation Factor 15) signals through the GFRAL receptor in the area postrema and nucleus tractus solitarius of the brainstem. This is outside the blood-brain barrier, allowing circulating GDF-15 to directly modulate feeding behavior. [Tier 1 — well-characterized pathway, Mullican et al. 2017, Emmerson et al. 2017] - **Appetite suppression**: GDF-15 is one of the most potent endogenous appetite suppressants. It induces nausea, food aversion, and reduced food intake. This is NOT a comfortable weight loss — it works through conditioned taste aversion pathways. [Tier 1] - **Body weight reduction**: Animal studies show dramatic weight loss with GDF-15 overexpression or administration. The effect is robust and reproducible. [Tier 1 — animal data] - **Metabolic improvement**: GDF-15-mediated weight loss improves insulin sensitivity, glucose tolerance, and lipid profiles. Whether this is independent of weight loss is debated. [Tier 2] ### Stress Response System - **Stress cytokine**: GDF-15 is massively upregulated by cellular stress — mitochondrial dysfunction, tissue injury, inflammation, cancer, and metabolic stress. Levels can increase 10-100x in disease states. [Tier 1] - **Integrated stress response**: GDF-15 is downstream of the mitochondrial integrated stress response (ISR). When mitochondria are stressed, GDF-15 is produced as a hormonal signal. [Tier 1] - **Biomarker role**: Elevated GDF-15 is associated with poor prognosis in heart failure, cancer, kidney disease, and frailty. It may be more useful as a biomarker than a therapeutic target. [Tier 1 — extensive biomarker data] ### Cardiovascular System - **Heart failure marker**: GDF-15 is one of the strongest prognostic biomarkers in heart failure, independent of BNP/NT-proBNP. [Tier 1] - **Cardioprotective vs. pathological**: Debate exists about whether elevated GDF-15 in heart disease is protective (adaptive stress response) or pathological (marker of damage). Probably both, context-dependent. [Tier 2] ### Cancer Biology - **Cancer cachexia**: GDF-15 is significantly elevated in many cancers and contributes to cancer-associated cachexia (muscle wasting and appetite loss). Anti-GDF-15 antibodies are being developed to combat cachexia. [Tier 1] - **Immune evasion**: Some evidence that tumor-derived GDF-15 helps cancers evade immune surveillance. [Tier 2] ### Aging/Longevity - **Aging biomarker**: GDF-15 increases with age and is associated with frailty, sarcopenia, and mortality risk. It is one of the most age-associated circulating proteins. [Tier 1] - **Paradox**: Interventions that increase GDF-15 (like metformin) are associated with longevity, yet high baseline GDF-15 predicts poor outcomes. This paradox is unresolved — the context (cause of elevation) likely matters. [Tier 2]

Practitioner Guide

## GDF-15 — Practitioner Guide ### Clinical Profile GDF-15 is primarily important as a biomarker and physiological concept rather than as a therapeutic peptide. Understanding GDF-15 biology helps practitioners interpret lab values and understand metabolic stress responses. ### As a Biomarker - **Testing**: Available through specialty labs. Normal levels increase with age (typical range 200-1200 pg/mL in healthy adults, higher with age). - **Interpretation**: Markedly elevated levels (>2000-5000 pg/mL) suggest significant cellular/mitochondrial stress and warrant investigation. - **Monitoring**: Serial GDF-15 levels can track mitochondrial health, disease progression, and treatment response. - **Context matters**: Metformin raises GDF-15 (this may actually be part of its benefit mechanism). Exercise raises GDF-15 acutely. Cancer, heart failure, and kidney disease elevate GDF-15 chronically. ### Therapeutic Landscape - **Anti-GDF-15 antibodies**: Being developed for cancer cachexia (to block appetite suppression and muscle wasting in cancer patients). Not for general use. - **GDF-15 agonists**: Pharmaceutical interest as anti-obesity agents, but the nausea mechanism makes tolerability a major challenge. GLP-1 agonists achieve appetite suppression through better-tolerated mechanisms. - **Not a peptide therapy**: GDF-15 is not used as a standalone peptide therapy in clinical practice. Its importance is conceptual and diagnostic. ### How GDF-15 Knowledge Helps Clinical Practice - **Interpreting fatigue + weight loss**: If a patient has unexplained appetite loss, fatigue, and weight loss — check GDF-15. If markedly elevated, investigate for malignancy, mitochondrial dysfunction, or chronic organ disease. - **Metformin mechanism**: Understanding that metformin works partly through GDF-15/GFRAL signaling explains some of its appetite-suppressive effects and GI side effects. - **Mitochondrial health monitoring**: GDF-15 can be used alongside organic acids and lactate/pyruvate ratios to assess mitochondrial function. ### Clinical Observations - Patients on metformin who experience significant nausea/appetite loss may have high GDF-15 sensitivity - Cancer patients with high GDF-15 often benefit from appetite support strategies - GDF-15 levels tend to normalize when underlying stressors are addressed

Evidence

• GDF-15 and uEGF Independently Associate With CKD Progression in Children.

  Unknown et al. (2025) — Kidney Int Rep — PMID: 10.1016/j.ekir.2025.07.004

  In two pediatric CKD cohorts (4C n=671 with ESCAPE validation n=329), higher serum GDF-15 independently predicted CKD progression and improved risk stratification when combined with urinary EGF.

  moderate

• Human macrophage programming by GDF-15

  (2024) — PMID: 10.11588/heidok.00035704

  GDF-15 reprograms human macrophages into a tolerogenic phenotype, promotes angiogenesis, and modifies TGF-β signaling. It exhibits anti-inflammatory effects by altering gene expression related to cytokine signaling and macrophage function.

  emerging

• Biomarker GDF-15 in cardiology

  Authors not listed in queue metadata (2021) — Vnitrni Lekarstvi — PMID: 10.36290/vnl.2021.045

  Peer-reviewed cardiology review describes GDF-15 as a stress-responsive biomarker associated with incident heart failure, acute coronary syndrome complications, bleeding risk in anticoagulated atrial fibrillation, and overall cardiometabolic risk, while noting its role is prognostic rather than definitively therapeutic.

  moderate

Research Summary

## GDF-15 — Research Summary ### Tier 1 (Strong Clinical Evidence) - **GFRAL receptor identification**: 2017 landmark studies (four independent groups) identified GFRAL as the GDF-15 receptor in brainstem. Well-validated. - **Biomarker data**: Extensive data validating GDF-15 as a prognostic biomarker in heart failure, cancer, CKD, and aging. Multiple large cohort studies. - **Cancer cachexia**: Established role of GDF-15 in cancer-associated appetite loss and wasting. Anti-GDF-15 antibodies in clinical development. - **Metformin mechanism**: GDF-15 identified as a mediator of metformin's weight and metabolic effects (Coll et al., 2020, Nature). ### Tier 2 (Moderate Evidence) - **Therapeutic obesity applications**: Animal studies showing weight loss with GDF-15 are robust. Human therapeutic development is early. - **Mitochondrial stress marker**: Well-characterized as downstream of ISR. Clinical utility as mitochondrial health marker is emerging. - **Aging biology**: Strong epidemiological data linking GDF-15 to aging outcomes. Causal role vs. biomarker role is being investigated. ### Tier 3 (Emerging) - **Therapeutic peptide use**: Not currently used as exogenous peptide therapy. All therapeutic development is pharmaceutical (antibodies, small molecules). - **Clinical utility as monitoring tool**: Practitioners are beginning to use GDF-15 levels for mitochondrial health assessment. ### Key Research Gaps - The paradox of GDF-15 (metformin raises it beneficially, but high levels predict poor outcomes) needs resolution - Optimal use as a clinical biomarker needs standardization - Therapeutic window for GDF-15 agonism (obesity) vs. antagonism (cachexia) needs definition